
Beroni Group Limited, together with its subsidiaries, develops and sells smoking control products, air purifiers, water filters, and health care products and supplements in China, Australia, the United States, and Japan. It operates through Nicobloc, Fogibloc Air Purifier, Olansi Water Filter, Health Supplements, Cosmetic products, and Viral Diagnostic Kits segments. The company's products include NicoBloc, a smoking cessation/harm reduction product; and Fogibloc, an air purifier system. It also offers cosmetic products, such as V show rejuvenation liquids, hyaluronic acid moisturizing silk masks, and avocado poly-peptide intensive treatment silk masks. In addition, the company provides SARS-CoV-2 IgG/IgM antibody detection kit, as well as sells CII-ArboViroPlex rRT-PCR assay, a diagnostic kit used to detect viruses such as Zika, Dengue, Chikungunya, and West Nile. Further, it engages in the research and development of new drugs and clinical trial; gene detection and diagnosis, as well as sale of cell therapies for cancer and anti-aging treatments; developing new anti-cancer drugs; detection and diagnosis of infectious diseases; and e-commerce platform for pharmaceutical and healthcare products. Additionally, the company sells stem cell cosmetic products. The company was founded in 2014 and is headquartered in Sydney, Australia.
Beroni Group Limited trades as BNIGF on OTC. The company is classified in Industrials / Conglomerates and reports in USD.
The current profile places the business in Conglomerates. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.
Detailed operating-segment data is not available for this symbol yet.
Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.
The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.
Beroni Group Limited can be compared against peers such as CirTran Corporation, Critical Solutions, Inc., Digital Locations, Inc., Drone Services USA, Inc., Element Global, Inc., Majic Wheels Corp..
A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.
Current signals to investigate include market capitalization of $213,144, beta of -1.87, and return on equity of N/A.
This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.
Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.
BNIGF currently shows total debt of N/A and beta of -1.87. Missing data should be treated as a research gap, not as low risk.
Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.
No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.
Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.
No recent SEC-style filings are available for this symbol yet.
Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.
Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.
Company website: https://www.beronigroup.com
For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.